
US-based G1 Therapeutics develops innovative treatments for oncology and breast cancer.
Founded in Durham, United States, G1 Therapeutics is a pharmaceutical company dedicated to developing next-generation cancer therapies. Their core mission is to improve the lives and outcomes of people living with cancer, with a particular focus on oncology and breast cancer treatments. G1 Therapeutics offers innovative therapeutic solutions aimed at addressing unmet medical needs in the healthcare sector within the United States.
Notable affiliated individuals include key researchers and industry experts who have contributed to the company's advancements. G1 Therapeutics has attracted significant investment from leading healthcare investors, bolstering its research and development efforts. Key achievements include the development of novel therapeutics that have shown promise in clinical trials, positioning the company as a significant player in the oncology treatment landscape. The overall impact of G1 Therapeutics is reflected in its commitment to enhancing cancer care and improving patient outcomes.

Traws Pharma

Revolution Medicines
revmed.com

Advanced Cancer Therapeutics

Clovis Oncology

OnCusp Therapeutics
oncusptx.com

BeOne Medicines
beigene.com

Palm Therapeutics

Checkpoint Therapeutics
checkpointtx.com

Tango Therapeutics
tangotx.com

MacroGenics
macrogenics.com

Kronos Bio

Cullinan Oncology

Gliknik
gliknik.com

TG Therapeutics
tgtherapeutics.com

Blueprint Medicines
Companies similar to G1 Therapeutics include Traws Pharma, Revolution Medicines, Advanced Cancer Therapeutics and Clovis Oncology.
G1 Therapeutics was founded in 2008.
G1 Therapeutics' headquarters is located in Triangle (historical), NC, US.
G1 Therapeutics' most recent funding round was for $50M (USD) in November 2022.
As of Nov 17, 2022, G1 Therapeutics has raised a total of $697.4M (USD).
G1 Therapeutics has 170 employees as of Feb 6, 2024.